English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To compare the effects of deflazacort (DEFLA) vs. prednisone (PRED) on bone mineral density (BMD), body composition, and lipids, 24 patients with end-stage renal disease were randomized in a double blind design and followed 78 weeks after kidney transplantation. BMD and body composition were assessed using dual energy x-ray absorptiometry. Seventeen patients completed the study. Glucocorticosteroid doses, cyclosporine levels, rejection episodes, and drop-out rates were similar in both groups. Lumbar BMD decreased more in PRED than in DEFLA (P &lt; 0.05), the difference being particularly marked after 24 weeks (9.1 +/- 1.8% vs. 3.0 +/- 2.4%, respectively). Hip BMD decreased from baseline in both groups (P &lt; 0.01), without intergroup differences. Whole body BMD decreased from baseline in PRED (P &lt; 0.001), but not in DEFLA. Lean body mass decreased by approximately 2.5 kg in both groups after 6-12 weeks (P &lt; 0.001), then remained stable. Fat mass increased more (P &lt; 0.01) in PRED than in DEFLA (7.1 +/- 1.8 vs. 3.5 +/- 1.4 kg). Larger increases in total cholesterol (P &lt; 0.03), low density lipoprotein cholesterol (P &lt; 0.01), lipoprotein B2 (P &lt; 0.03), and triglycerides (P = 0.054) were observed in PRED than in DEFLA. In conclusion, using DEFLA instead of PRED in kidney transplant patients is associated with decreased loss of total skeleton and lumbar spine BMD, but does not alter bone loss at the upper femur. DEFLA also helps to prevent fat accumulation and worsening of the lipid profile.

the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism

Effects of Deflazacort<i>Versus</i>Prednisone on Bone Mass, Body Composition, and Lipid Profile: A Randomized, Double Blind Study in Kidney Transplant Patients<sup>1</sup>

Effects of DeflazacortVersusPrednisone on Bone Mass, Body Composition, and Lipid Profile: A Randomized, Double Blind Study in Kidney Transplant Patients1

Effects of DeflazacortVersusPrednisone on Bone Mass, Body Composition, and Lipid Profile: A Randomized, Double Blind Study in Kidney Transplant Patients¹